We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Renal Cell Carcinoma

Journal Scan / Research · February 15, 2021

Cabozantinib Real-World Effectiveness for the Treatment of Metastatic RCC

Cancer Medicine


Additional Info

Disclosure statements are available on the authors' profiles:

Cancer Medicine
Cabozantinib Real-World Effectiveness in the First-Through Fourth-Line Settings for the Treatment of Metastatic Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium
Cancer Med 2021 Jan 18;[EPub Ahead of Print], CL Gan, S Dudani, JC Wells, F Donskov, SK Pal, N Dizman, N Rathi, B Beuselinck, F Yan, AA Lalani, A Hansen, B Szabados, G de Velasco, B Tran, JL Lee, UN Vaishampayan, GA Bjarnason, M Subasri, TK Choueiri, DYC Heng

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading